Dr. Carolyn Baglole was featured in the July 2019 CCIC Newsletter. Her research was profiled in their monthly research highlights. Read the newsletter excerpt below.
Dr. Baglole received her BSc and MSc from the University of Prince Edward Island, and completed her PhD at the University of Calgary. She then did postdoctoral work in the fields of lung biology/toxicology in the Department of Environment Medicine at the University of Rochester (Rochester NY) before returning to Canada at McGill University.
Dr. Baglole’s translational research program seeks to identify novel cellular and molecular pathways that regulate the pathogenesis of chronic lung diseases. Her main research focus is to understand how these environmental exposures contribute to pathogenic mechanisms such as chronic inflammation and cell death (apoptosis) that drive the development of diseases such as chronic obstructive pulmonary disease (COPD) and lung cancer.
In relation to the CCIC, her lab is currently examining how various forms of inhaled cannabis and/or cannabinoids affects lung and immune function. Using pre-clinical models, her team will investigate activation of cellular signaling pathways by exposure to cannabis/cannabinoids, how cannabis exposure effects immune cell numbers and function and whether newer forms of inhaled cannabis products impact lung function. Working with clinicians and other scientists, she is developing an interdisciplinary program for biomedical cannabis research to explore the full potential of cannabis and cannabinoids in human health and disease. For this, she will have a state-of-the-art inhalation facility. This is important, as the most common way to consume cannabis is through inhalation (of smoke or vaporized cannabis/cannabinoids). With this, she will be able to deliver inhaled cannabis and cannabis-derived cannabinoids/novel drugs in a real-world scenario to assess efficacy in disease models and understand the immune-medicated mechanisms involved in the potential therapeutic benefits of cannabis.